Updated:
Araris Biotech
Araris Biotech develops antibody-drug conjugates in Zurich using a one-step linker platform to attach payloads directly to native antibodies.
Araris Biotech
Araris Biotech was established in Zurich, Switzerland, to commercialize a linker-conjugation platform for antibody-drug conjugates. The technology enables site-specific payload attachment to native antibodies, bypassing the need for antibody re-engineering — a step that typically complicates manufacturing and introduces heterogeneity. Early work emerged from the Paul Scherrer Institute and ETH Zurich. Proprietary linker technology defines the firm's strategic positioning. Araris targets well-validated oncology antigens with conjugates carrying topoisomerase I inhibitor payloads, a class that includes deruxtecan and exatecan derivatives. Preclinical data on candidates aimed at targets such as NaPi2b and BCMA suggests high drug-to-antibody ratio uniformity and strong tumor-killing activity. The firm also secures revenue through technology partnerships, including a disclosed research collaboration and license option agreement with Chugai Pharmaceutical, which provides upfront and milestone economics. The firm operates from its Zurich headquarters with no disclosed additional offices. Headcount is not publicly stated. In December 2024, Araris presented preclinical data at the San Antonio Breast Cancer Symposium on NaPi2b-targeting ADCs, demonstrating tumor regression in triple-negative breast cancer models (per the firm's official communications). Araris Biotech's structural differentiator lies in its direct, one-step conjugation chemistry. Unlike cell-line engineering or enzymatic approaches that force a trade-off between homogeneity and simplicity, the Araris platform modifies a single native interchain disulfide bond to yield homogeneous ADCs without the cost and risk of engineering the antibody backbone. This elegance is the pitch to partners: faster candidate generation, fewer manufacturing liabilities, and a path to better therapeutic indices — a model that positions Araris less as a drug developer and more as a technology enabling layer for oncology pipelines across the industry.
General information
Firm type
Asset Manager
Year founded
—
AUM
Undisclosed
Location
Region
Europe
Country
Switzerland
City
Zurich
Corporate office
Zurich, Switzerland
Sector focus
Frequently asked questions
What is Araris Biotech's core technology platform?
Araris has built a linker-conjugation platform that attaches cytotoxic payloads directly to native antibodies without any prior antibody engineering. The chemistry targets a specific interchain disulfide bond, creating site-specific, homogeneous antibody-drug conjugates in a single step. This eliminates the need for cysteine engineering, glycan remodeling, or enzymatic modifications commonly used in ADC production.
Does Araris partner its technology with external companies?
Yes. Araris operates a partnership model alongside its internal pipeline. The firm secured a research collaboration and license option agreement with Chugai Pharmaceutical, disclosed publicly. Under such deals, Araris typically provides its linker technology and know-how, while the partner supplies antibodies of interest against agreed oncology targets.
What payloads does Araris use in its ADCs?
Araris focuses on topoisomerase I inhibitor payloads, a validated class in ADCs that includes molecules like deruxtecan and exatecan. The firm's linker chemistry is compatible with these payloads, enabling high drug-to-antibody ratios and potent bystander killing in tumor models, as shown in preclinical studies presented at major oncology conferences.
What is the geographic footprint of Araris Biotech?
The company is headquartered in Zurich, Switzerland, with its research and operational activities conducted from that location. There is no public disclosure of additional offices or subsidiaries outside of Switzerland.
Which cancer targets are in Araris's disclosed pipeline?
Publicly presented data has focused on oncology targets including NaPi2b, a sodium-dependent phosphate transport protein overexpressed in several cancers including ovarian and triple-negative breast cancer, and BCMA, a well-known multiple myeloma target. The firm's linker platform is target-agnostic, so the pipeline may span additional undisclosed solid-tumor and hematologic antigens across partner programs.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on asset managers?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: